Digital Therapeutics (DTx) are evidence-based health interventions driven by software programmes. DTx can also be a part of an adjunctive solution combining a software-based solution with traditional medicinal products as a way of levelling up consumer outcomes. While it is an emerging space, it has seen significant growth with multiple regulatory approved products already available in the market.
Reckitt Benckiser is seeking software-based solutions (apps, web-based solutions, voice apps etc.) that either:
Solutions are intended for consumer use, i.e.: users who suffer from a condition or disease that is treatable with digital therapy. Portable and convenient forms that can be used on-the-go are preferred.
Solutions must have strong clinical evidence to back up their efficacy claims and should address the following areas of interest:
Submit your proposal here.
We are not interested in products tied to or associated with hardware devices e.g. digital inhaler, blood glucose monitors etc.
